8-K

                          SECURITIES AND EXCHANGE COMMISSION
                                   Washington, D.C.

                                       FORM 8-K

                    CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
                        OF THE SECURITIES EXCHANGE ACT OF 1934

                            Date of Report: March 9, 1999


                             BIO-MEDICAL AUTOMATION, INC.
               ------------------------------------------------------
               (Exact name of Registrant as specified in its charter)

                           Commission file number: 0-16335

              Colorado                                  84-0922701
    -------------------------------              ----------------------
    (State or other jurisdiction of                  (IRS Employer
    incorporation or organization)               Identification Number)


  7450 East Jewell Ave, Suite A, Denver, Colorado          80231   
  -----------------------------------------------        ---------
  (Address of principal executive offices)               (Zip Code)


            Registrant's telephone number, including area code:
                                (303) 368-0401

                       OZO Diversified Automation, Inc.
                    --------------------------------------------
                    former name or former address, if applicable




Item 2.  Acquisition or Disposition of Assets.

     On March 9, 1999, the Company completed the sale of substantially all of 
its assets to JOT Automation, Inc. ("JOT") as described in the Company's 
proxy statement for its shareholders meeting which was sent to all 
shareholders of record on December 31, 1998.   (See Item 5, below.)  JOT is a 
wholly-owned Texas-based subsidiary of JOT Automation Group Oyj ("JOT 
Parent"), a Finnish corporation which has its common stock registered on the 
Helsinki Stock Exchange.  The Company has entered into an Asset Purchase 
Agreement (the "Agreement"), dated November 4, 1998 (and amended December 15, 
1998), with JOT. JOT is engaged in the business of production automation and 
robotics for use within the electronics industry.  The Company sold to JOT 
all of its assets relating to its routing and depaneling business in exchange 
for $920,000 and the assumption of the operating liabilities related to the 
Company's business assets (the "Transaction").  

     JOT acquired all of the current assets of the Company, current operating 
liabilities, and the fixed assets used in the production of depaneling 
equipment.  As of September 30, 1998, current assets totaled $509,984, 
current operating liabilities totaled $219,152, and fixed assets  (net of 
accumulated depreciation) totaled $145,314.  JOT is also acquiring the rights 
to the OZO name and trademark, copyrighted software, and the Company's 
customer lists. Virtually all of the Company's employees will become JOT 
employees, and the current production facility in Denver will continue to 
operate in much the same manner as it has before the Transaction.

     The Company (which has changed its name to Bio-Medical Automation, Inc. 
as a result of the Transaction) will  retain certain assets which include the 
net cash proceeds of the Transaction (approximately $600,000, calculated 
after deducting from the purchase price an amount paid to JOT to reimburse it 
for certain expenditures made by OZO for excluded assets, and after repaying 
certain liabilities of the Company (including the finder's fee discussed 
below) which JOT did not assume).  The Company will also retain a new 
technology currently under development.  None of the Company's current 
products will be retained. Because the new technology represents a 
significant departure from  the current product line, it is unlikely any of 
the Company's current  customers would continue as customers after the new 
technology is commercially available.

     JOT licensed certain technologies back to the Company to allow the 
Company to continue to use copyrighted motion control and automation software 
in certain fields of use.  These fields of use include, among other things, 
the manipulation of biological systems in order to accomplish a wide range of 
research, medical and commercial objectives.  This is a fully paid, 
non-revocable, transferable, royalty-free license in perpetuity offered by 
JOT to the Company.

     The Agreement provides for a 90-day transition period (the "Transition 
Period") during which the Company's former employees hired by JOT may provide 
certain transitional services to the Company for a specified hourly rate. 
During the transitional period, the Company will sublease office space from 
JOT for $200 per month.  After the Transitional Period, the Company will be 
required to relocate its offices.

     The Company had entered into an investment banking agreement in June 
1998 with Catalyst Financial Corp. of Miami, Florida ("Catalyst").  The 
primary goal of this investment banking relationship was to obtain financial 
consulting services related to merger and acquisition activities and among 
other things, to assist the Company in developing a financial summary of the 
company and its business; identifying, developing, and providing 
introductions to suitable acquisition 



candidates; assisting in the negotiations of terms and the structure of any 
transactions that came under review; and working closely with the Company and 
its other advisors to orchestrate a closing.  It was the Company's intention 
to use Catalyst as its primary advisor in its efforts to facilitate its  
restructuring.  The contract did not require that any monthly fee be paid to 
Catalyst.  As a result of the contract, the Company will pay Catalyst 
approximately $40,000.  As a result of the completion of the Transaction, the 
agreement has expired.

     At the time the Company entered into the agreement with Catalyst, Scott 
Salpeter, a director of the Company, was an employee and officer of Catalyst. 
Steve Bronson who owned more than 10% of the Company's outstanding stock, was 
also affiliated with Catalyst.  Subsequently Mr. Salpeter and Mr. Bronson 
separated, and Mr. Salpeter formed a new corporation known as Capitalink. 
Capitalink assumed the contract effective October 1, 1998. Mr. Salpeter 
abstained from the Board's vote with respect to the Capitalink agreement and 
the fee.

     In connection with the closing of the Transaction, David J. Wolenski, 
President, Chief Executive Officer and a director of the Company, and David 
W. Orthman, Director of Research and Development, Secretary-Treasurer and a 
director of the Company entered into three-year employment agreements with 
JOT. As noted below, Mr. Orthman resigned his positions as an executive 
officer of the Company.  Mr. Orthman will serve as Director of Research and 
Development of a designated subsidiary  of JOT.  In addition to his serving 
as President and director of the Company, Mr. Wolenski is serving as 
President of a designated subsidiary of JOT.

Item 5.  Other Events.

SHAREHOLDERS' MEETING

     On March 1, 1999, the shareholders of the Company approved amendments to
the articles of incorporation of the Company which:

- -  approved the sale of substantially all of the Company's assets to JOT
   Automation, Inc., and (as a consequence of the sale) approved the change of 
   the name of the Company. Holders of fewer than 200 shares of the Company's 
   common stock exercised their statutory right to dissent from the Transaction.

- -  approved a proposal to adopt a new Article IX to  the Company's Restated
   Articles of Incorporation, as amended, to provide for the limitation of 
   certain liabilities of the Company's directors to the Company and its 
   shareholders as permitted under Section 7-108-402(1) of the Colorado Business
   Corporation Act.

     The meeting was adjourned until April 22, 1999, at which time the 
shareholders will consider a proposed amendment to Article VI of the 
Company's Restated Articles of Incorporation to reduce the vote required by 
shareholders to approve asset dispositions, mergers, consolidations or 
exchanges, and any other matter which would require an amendment to the 
Company's Restated Articles of Incorporation, as amended, from two-thirds to 
a majority.

CHANGES IN THE BOARD OF DIRECTORS AND OFFICERS



     Because of changes in personal circumstances, Scott E. Salpeter and 
Brantley J. Halstead resigned from the Board of Directors of the Company 
effective March 5, 1999.  Mr. Halstead has agreed to continue to assist the 
Company as its Chief Financial Officer until the Company finds a suitable 
replacement.  

     In accordance with his obligations to JOT as described in the proxy 
statement, David Orthman has resigned as an officer of the Company, but will 
continue as a member of the Board of Directors and will continue to work as a 
consultant to the Company to assist the Company in completing the research 
and development necessary to complete the prototype  micro-robotic device as 
described in the proxy statement.

     David J. Wolenski will continue to serve as president of the Company and 
as a member of the Company's Board of Directors.

FORWARD-LOOKING INFORMATION QUALIFICATION

     The future conduct of the Company's business is dependent upon a number 
of factors and there is no assurance  that the Company will be able to 
conduct its operations as contemplated in this report.  Certain statements  
contained in this report using the terms "may", "expects to", and other terms 
denoting future possibilities, are forward-looking statements.  The accuracy 
of these statements cannot be guaranteed as they are subject to a variety of 
risks which are beyond the Company's ability to predict or control.  These 
risks may cause actual results to differ materially from the projections or 
estimates contained in this report.  These risks include, but are not limited 
to, the possibility that the described operations or other activities will 
not be completed on economic terms, if at all.  The research and development 
of technology products is an enterprise attendant with high risk.  There can 
be no assurance that the Company will succeed in successfully developing a 
product in the bio-medical or bio-technical fields, and it is important that 
each person reviewing this report understands the significant risks which 
accompany the establishment of the completion of the Transaction and the 
conduct of the Company's future operations.

Item 7.  Financial Statements and Exhibits

(A) and (B) Financial Statements 

     Pro forma financial information (to be filed by amendment)

(C)  Exhibits

     3.1  Articles of Amendment to the Company's Articles of Incorporation



                                  SIGNATURES

     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, 
as amended,  the  registrant has duly caused this report to be signed on its 
behalf by the undersigned hereunto duly authorized.

                                       BIO-MEDICAL AUTOMATION, INC.

March 18, 1999                         By: /s/ David J. Wolenski
                                          -----------------------------
                                          David J. Wolenski, President

EX-3.1

                                     AMENDMENT TO
                              ARTICLES OF INCORPORATION
                                         FOR
                           OZO DIVERSIFIED AUTOMATION, INC.
                                A COLORADO CORPORATION


     RESOLVED, that pursuant to the provisions of the Colorado Business 
Corporation Act, and as approved by the holders of a majority of the 
outstanding voting stock at a meeting of the shareholders held on March 1, 
1999, and a recommendation of the Board of Directors of OZO Diversified 
Automation, Inc. (the "Corporation"), the Restated Articles of Incorporation 
of the Corporation, as amended (the "Articles"), are further amended as set 
forth herein. 

1.   ARTICLE 1 of the Articles be and hereby is amended to read as follows:  

          The name of the Corporation is Bio-Medical Automation, Inc.

2.   ARTICLE IX of the Articles be and hereby is amended to read as follows:

                    ARTICLE IX - LIMITATION ON DIRECTOR LIABILITY

          A director of the Corporation shall not be personally liable to
     the Corporation or to its shareholders for monetary damages for breach
     of fiduciary duty as a director; except that this provision shall not
     eliminate or limit the liability of a director to the Corporation or
     to its  shareholders for monetary damages otherwise existing for (i)
     any breach of the director's duty of loyalty to the Corporation or to
     its shareholders;  (ii) acts or omissions not in good faith or which
     involve intentional  misconduct or a knowing violation of law; (iii)
     acts specified in Section 7-108-403 of the Colorado Business
     Corporation Act; or (iv) any transaction  from which the director
     directly or indirectly derived any improper personal benefit.  If the
     Colorado Business Corporation Act is hereafter amended to eliminate or
     limit further the liability of a director, then, in addition to the
     elimination and limitation of liability provided by the preceding 
     sentence, the liability of each director shall be eliminated or
     limited to the fullest extent permitted by the Colorado Business
     Corporation Act as so amended.  Any repeal or modification of this
     Article IX shall not adversely affect any right or protection of a
     director of the corporation under this Article IX as in effect
     immediately prior to such repeal or modification with respect to any
     liability that, but for this Article IX, would have accrued prior to
     such repeal or modification.

3.   The number of shares that voted for this amendment was sufficient for
     approval.

4.   This amendment to the Articles shall become effective at the close of
     business on filing with the Secretary of State of Colorado.

                                                              Page 1 of 2


     IN WITNESS WHEREOF, OZO Diversified Automation, Inc. has caused this
amendment to the Corporation's Restated Articles of Incorporation to be signed
this 17th day of March, 1999.


                                       OZO DIVERSIFIED AUTOMATION, INC.


                                       By /s/ David J. Wolenski
                                         ------------------------------
                                         David J. Wolenski, President




                                                              Page 2 of 2